Journal Mobile Options
Table of Contents
Vol. 83, No. 4, 2012
Issue release date: August 2012
Oncology 2012;83:234–238
(DOI:10.1159/000341351)

Taxanes for Ovarian Cancer during Pregnancy: A Systematic Review

Zagouri F. · Sergentanis T.N. · Chrysikos D. · Filipits M. · Bartsch R.
aComprehensive Cancer Center Vienna, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; b1st Propaedeutic Surgical Department, Hippocrateio Hospital, University of Athens, Athens, Greece

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Ovarian cancer in pregnancy is uncommon; however, this diagnosis adds complexity to cancer treatment recommendations. This is the first systematic review to synthesize all available data and evaluate the efficacy and safety of taxanes during pregnancy in ovarian cancer. Methods: This systematic review was performed in accordance with PRISMA guidelines. All studies that examined the efficacy and safety of taxanes administered during pregnancy in ovarian cancer, regardless of sample size, were considered eligible. Results: Overall, 8 articles (11 pregnancies, 12 newborns) were retrieved for paclitaxel and 1 for docetaxel (1 pregnancy, 1 newborn). In 92.31% of cases a healthy child was born, with a median follow-up of 20 months. The mean weight of the babies at delivery was 2,381 g. One study providing follow-up until the 11th year of age reported a case of attention deficit disorder. In 6 out of 8 case reports providing survival data, the mother was alive and disease free at the end of follow-up (ranging from 9.75 to 45 months). Conclusion: Taxanes may play a significant role in the treatment of ovarian cancer patients during the 2nd and 3rd trimesters. Before that, the risk of abortion or congenital anomalies is increased.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, Goldwasser F: Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 2008;19:607–613.
  2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds): SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER website. 2011. http://seer.cancer.gov/csr/1975_2008/.
  3. Barut A, Arikan I, Barut F, Harma M, Harma MI, Payasli B: Ovarian cancer during pregnancy. J Pak Med Assoc 2011;61:914–916.

    External Resources

  4. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M, ESMO Guidelines Working Group: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):23–30.

    External Resources

  5. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–e34.
  6. Serkies K, Węgrzynowicz E, Jassem J: Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature. Arch Gynecol Obstet 2011;283(suppl 1):97–100.

    External Resources

  7. Doi D, Boh Y, Konishi H, Asakura H, Takeshita T: Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. Arch Gynecol Obstet 2009;280:633–636.

    External Resources

  8. Modares Gilani M, Karimi Zarchi M, Behtash N, Ghaemmaghami F, Mousavi AS, Behnamfar F: Preservation of pregnancy in a patient with advanced ovarian cancer at 20 weeks of gestation: case report and literature review. Int J Gynecol Cancer 2007;17:1140–1143.
  9. Hubalek M, Smekal-Schindelwig C, Zeimet AG, Sergi C, Brezinka C, Mueller-Holzner E, Marth C: Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma. Arch Gynecol Obstet 2007;276:179–183.

    External Resources

  10. Mantovani G, Gramignano G, Mais V, Melis GB, Parodo G, Carrucciu GM: Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review. Eur J Obstet Gynecol Reprod Biol 2007;131:238–239.
  11. Méndez LE, Mueller A, Salom E, González-Quintero VH: Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol 2003;102:1200–1202.
  12. Sood AK, Shahin MS, Sorosky JI: Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 2001;83:599–600.
  13. Rouzi AA, Sahly NN, Sahly NF, Alahwal MS: Cisplatinum and docetaxel for ovarian cancer in pregnancy. Arch Gynecol Obstet 2009;280:823–825.
  14. Cardonick E, Usmani A, Ghaffar S: Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 2010;33:221–228.
  15. Guarneri V, Piacentini F, Barbieri E, Conte PF: Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:15215–15218.

    External Resources

  16. Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, Rouzier R: Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010;21:425–426.
  17. Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, Ross MI, Perkins GH, Gwyn K, Theriault RL: Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 2004;5:317–319.
  18. Gadducci A, Cosio S, Fanucchi A, Nardini V, Roncella M, Conte PF, Genazzani AR: Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res 2003;23:5225–5229.
  19. Palaia I, Pernice M, Graziano M, Bellati F, Panici PB: Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report. Am J Obstet Gynecol 2007;197:e5–e6.
  20. Li J, Wang LJ, Zhang BZ, Peng YP, Lin ZQ: Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review. Arch Gynecol Obstet 2011;284:779–783.

    External Resources

  21. Azim HA Jr, Scarfone G, Peccatori FA: Carboplatin and weekly paclitaxel for the treatment of advanced non-small cell lung cancer (NSCLC) during pregnancy. J Thorac Oncol 2009;4:559–560.

    External Resources

  22. García-González J, Cueva J, Lamas MJ, Curiel T, Graña B, López-López R: Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy. Clin Transl Oncol 2008;10:375–376.
  23. Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N, ESMO Guidelines Working Group: Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v266–v273.

    External Resources

  24. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer – Version 2.2011. http://www.nccn.com.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50